Industry News: AstraZeneca collaborates with Silence Therapeutics to develop siRNA therapeutics

The collaboration aims to develop novel, targeted treatments to address significant unmet needs

26 Mar 2020


AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases.

This multi-target collaboration will harness Silence’s established siRNA platform to identify and progress liver-based targets, as well as developing new delivery approaches for targeting other tissues such as the heart, lung and kidney. Targeted delivery to these other tissues represents a new opportunity to treat Cardiovascular, Renal, Metabolic and Respiratory diseases.

Mene Pangalos, EVP BioPharmaceuticals R&D, AstraZeneca said “This collaboration with Silence adds an exciting new modality, siRNA, into our drug discovery toolbox. Importantly we can apply this drug modality across our key therapy areas in cardiovascular, renal and metabolism and respiratory to target novel pathways not amenable to more traditional drug discovery approaches.”

Iain Ross, Executive Chairman at Silence said “We are delighted to announce this collaboration with AstraZeneca as it is a further validation of our proprietary siRNA platform. It not only provides us with an opportunity to collaborate on specific liver expressed gene targets but also to work with a leading company to achieve targeted delivery of siRNA molecules to other tissues including heart, kidney and lung.”

Small interfering RNA (siRNA) are double-stranded RNA molecules that offer new opportunities for therapeutic intervention because they act inside the cell to influence protein production. They do this by targeting RNA to prevent the production of disease-causing proteins.

Want more of the latest science news straight to your inbox? Become a member of SelectScience for free today>>